title: The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines.
abstract: The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Program has generated a comprehensive series of documents regarding the management of atrial fibrillation (AF) between 2010 and 2014. The guidelines provide evidence-based consensus management recommendations in a broad range of areas. These guidelines have proven useful in informing clinical practice, but often lack detail in specifications related to practical application, particularly for areas in which the evidence base is limited or conflicting. Based on feedback from the community, the CCS Atrial Fibrillation Guidelines Committee has identified a number of areas that require clarification to address commonly asked practical questions related to guidelines application. In the present article a number of such questions are presented and suggestions about how they can be answered are suggested. Among the issues considered are: (1) What duration of AF is clinically significant? (2) How are the risk factors in the CCS Algorithm for selecting anticoagulation therapy derived and defined? (3) How is valvular heart disease defined and how do different forms of valve disease affect the choice of anticoagulant therapy for AF patients? (4) How should we quantify renal dysfunction and how does it affect therapeutic choices? The response to these questions and the underlying logic are provided, along with an indication of future research needed where no specific approach can presently be recommended based on the literature.
authors.affiliation: Montreal Heart Institute and Department of Medicine, Université de Montréal, Montreal, Québec, Canada.
authors.forename: Laurent
authors.initials: L
authors.lastname: Macle
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: John A
authors.initials: JA
authors.lastname: Cairns
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jason G
authors.initials: JG
authors.lastname: Andrade
authors.affiliation: Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.
authors.forename: L Brent
authors.initials: LB
authors.lastname: Mitchell
authors.affiliation: Montreal Heart Institute and Department of Medicine, Université de Montréal, Montreal, Québec, Canada.
authors.forename: Stanley
authors.initials: S
authors.lastname: Nattel
authors.affiliation: Southlake Regional Health Centre, Newmarket, Ontario, Canada. Electronic address: atul.verma@utoronto.ca.
authors.forename: Atul
authors.initials: A
authors.lastname: Verma
mesh_terms: D000465:Algorithms; D000925:Anticoagulants / Q000145:classification / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D002170:Canada; D002309:Cardiology; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D012955:Societies, Medical; D020521:Stroke / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants